up to now, clinical trials on GLP-one drugs have demonstrated their benefits being a secondary prevention Device for heart problems (CVD), which means they are able to reduce the chance of the coronary heart assault or https://europeantimes.news/2024/08/belgium-battle-drugs-alcohol-hope/